additive for the HIV-1 LTR in the context of adenovirus and they appear to act at the transcriptional level. As in HeLa cells, the adenovirus-borne HIV-l LTR is inactive in the absence of a trans-activator in H9 and Jurkat cells, two human leukemic T-cell lines. This suggests that recombinant adenoviruses have diagnostic potential for the detection of trans-activators of the HIV-l LTR that are present in circulating human lymphocytes.
Transcription of human immunodeficiency virus 1 (HIV-1), the causative agent of acquired immune deficiency syndrome (AIDS) (1, 2) , is directed by the HIV-1 long terminal repeat (LTR) sequences. The HIV-1 LTR is composed of several regulatory elements: a negative regulatory element (located between nucleotides -340 and -185, relative to the cap site), a core enhancer (-105 to -80), three SP1 binding sites (-76 to -48), a "TATA box" (-26 to - 22) , and an element termed TAR (-17 to + 54) (3) (4) (5) (6) (7) (8) . The TAR element confers responsiveness to tatIII, a HIV-1-encoded trans-acting protein. The mechanism of action of tatIlf is unclear; experiments involving transfection of plasmid DNAs have suggested transcriptional regulation (7, 9, 10) , posttranscriptional regulation (11) , or a combination of the two (12) (13) (14) (15) . The course of AIDS, from initial infection with HIV-1 to manifestation of clinical symptoms, may be influenced by superinfection with other viruses capable of activating latent HIV-1. Several DNA viruses, most notably herpes simplex virus 1, have been shown to stimulate HIV-1 LTR-directed gene expression (16) (17) (18) . The herpes gene products involved in this trans-activation have been identified as ICPO and ICP4 (19, 20) .
To study regulation of HIV-1 LTR-directed gene expression, we have inserted the HIV-1 LTR, fused to the chloramphenicol acetyltransferase (CAT) gene, into adenovirus (Ad) in place of the El region. This recombinant Ad, HIV-lCAT-Ad, contains nucleotides -453 to + 80 from the HIV-1 LTR. We also constructed a similar recombinant adenovirus, RSVCAT-Ad, containing the Rous sarcoma virus (RSV) LTR fused to the CAT gene. These two viruses allow efficient introduction of the retroviral promoters into cells containing various trans-acting control factors.
Transcription of wild-type Ad is under strict temporal regulation during the infectious cycle. The EIA gene is the first transcription unit expressed after infection and produces, by differential splicing, two major mRNAs whose sizes are 12S and 13S. They encode polypeptides that differ only by an additional internal 46 amino acids contained in the larger protein (21) (22) (23) (24) . Transcriptional activation of all other early Ad promoters is due primarily to the action of the 13S ElA protein (25) Construction of Recombinant Ad. To construct RSVCATAd, the Nde I/BamHI fragment, containing the RSVCAT sequences, was removed from plasmid pRSVCAT (31) and inserted into Ad by in vivo recombination in 293 cells by the method of Gluzman et al. (32) . HIV-lCAT-Ad was constructed identically using the Xho I/BamHI fragment from pU3RIII (33) . Recombinant viruses were propagated and titered in 293 cells. Their genome structures are shown in Fig.   1 .
Conditions (20 tug/ml), added 4 hr postinfection; at 12-hr intervals thereafter, the medium was removed and replaced with fresh medium with or without the drug. CAT assays were performed by the standard procedure (31) . After thin-layer chromatography, CAT assays were quantitated with an Ambis Beta Scan System (Automated Microbiology Systems, San Diego, CA). CAT activity is presented as relative units, with 1 unit defined as 1% conversion of chloramphenicol substrate to its acetylated forms by an extract from 5 x 105 cells during a 60-min incubation. Extracts with high CAT activity were diluted and/or incubated for short periods so that <50% of the chloramphenicol substrate was acetylated in the assay. All experiments were repeated a number of times; the data presented are from a single experiment.
Plasmid Transfections. HeLa cells were transfected by the calcium phosphate precipitation method. Cell extracts were prepared 48 hr after transfection, and assays were performed as described above. Units of activity in plasmid transfections are also as defined above. 41 ,000 units at 24 hr postinfection. Similarly, when a higher moi was used for HIV-1CAT (moi, 1000), CAT expression was <10 units of activity through 8 hr postinfection and increased exponentially thereafter. Both recombinant Ad expressed much higher levels of CAT activity at late times after infection of 293 cells than at comparable times after infection of HeLa cells (see below). This may, in part, reflect the fact that Ad infection proceeds more rapidly in 293 cells; higher levels of expression in HeLa cells might have been observed if later time points had been analyzed.
RESULTS
Since these recombinant Ad replicate in 293 cells, CAT expression could be affected by increased template concentrations. To monitor effects of DNA replication, infections with HIV-1CAT-Ad were also carried out in the presence of araC to prevent viral DNA replication. High levels of CAT activity (>10,000 units) were still observed when DNA replication was blocked but were slightly reduced relative to levels seen in the absence of the drug (data not shown). Control Cells were infected as indicated. All viruses were used at a moi of proteins (Table 4) . As in coinfection experiments, cotransfection of plasmid DNAs showed that the HIV-1 LTR was trans-activated by the ElA 13S, but not 12S, protein. The magnitude of trans-activation by the 13S ElA protein was considerably higher in coinfection of virus than in cotransfection of plasmids (100-fold vs. 4-fold; Table 3 ), perhaps reflecting a more efficient delivery of both the HIV-1 LTR and 13S EIA gene into cells.
Trans-Activation May Require a cis-Modification of the HIV-1 LTR. The kinetics of CAT expression in coinfections of HeLa cells with HIV-1CAT-Ad and wild-type or 13S Ad, or in single infection of 293 cells, are noteworthy. There is little expression up to 12 hr postinfection, and then it increases exponentially to 36 hr postinfection (Tables 1-3 ; Fig. 2 ). Because this activation occurs in the presence of araC, we infer that expression of an early Ad gene product is involved in transcriptional activation of the HIV-1 LTR, either directly or indirectly through a second viral or cellular trans-acting factor, and that it may require 12 hr for the appearance or activation of this factor(s).
We carried out a superinfection experiment, similar to those of Thomas and Mathews (37) and Gaynor and Berk (38) , to address this possibility. The superinfection was carried out in the presence of araC to prevent possible complications due to viral DNA synthesis. HeLa and HeLa/tatIII cells were first infected with wild-type Ad for 14 hr and then superinfected with HIV-1CAT-Ad. CAT activity was assayed in cell extracts prepared throughout superinfection (Table 5) . If the lag in expression of the HIV-1 LTR in coinfection is due to the time required for the appearance of an adenovirus-induced transcription factor, then in the superinfection experiment the LTR should be expressed with a greatly decreased lag. It is clear from Table 5 that expression of the HIV-1 LTR still undergoes a long lag period, although preinfected with wild-type Ad for 14 hr. We conclude that the 12-hr lag before expression cannot be simply explained by the time required for the build up of a trans-acting factor.
Although CAT mRNA levels and transcription rates of the HIV-1 LTR promoted CAT gene were not measured directly in the superinfection experiment shown in Table 5 , CAT assays appear to be a valid measure of relative transcription rates in the Ad vector system (29) . We feel that the most likely explanation for the result shown in Table 5 is that the HIV-1 LTR must undergo some cis modification-for instance, assembly of a transcription complex and this requires -12 hr-before it can be expressed from the Ad chromosome. Similar data and conclusions were reached by Gaynor and Berk in a study, using superinfection experiments, that analyzed transcription of Ad early region 3 (38) .
Expression of HIV-lCAT-Ad and RSVCAT-Ad in Human T-Cell Lines. Expression of HIV-1CAT-Ad and RSVCAT-Ad was monitored in two human T-cell leukemic lines, H9 and Jurkat. After single or coinfection of both cell lines, extracts were prepared 48 hr postinfection and assayed for CAT activity (Fig. 3) . HIV-1CAT-Ad expressed no detectable CAT activity in single infection in either H9 or Jurkat cells, a result similar to that obtained in HeLa cells. However, coinfection with wild-type Ad activated the HIV-1 LTR, carried out in the presence of araC, and all viruses were used at a moi of 50 pfu per cell. Cell extracts were prepared 2, 4, 7, 12, 27, and 31 hr postinfection, and relative CAT activity was determined as described in Tables 1-4 3 and 7) , or RSVCAT-Ad and wild-type Ad (lanes 4 and 8) , and 48 hr postinfection cell extracts were prepared and assayed for CAT activity. All viruses were used at a moi of 50 pfu per cell. Levels of CAT activity expressed were: 1, 5, 42, >90, <1, 9, 28, and >90 units (lanes 1-8, respectively) .
Biochemistry: Rice and Mathews 4204 Biochemistry: Rice and Mathews tatIII protein and Ad ElA proteins. In this system, the HIV-1 LTR contained in Ad is trans-activated by tatIlflargely, ifnot entirely, at the transcriptional level (29) . Transcriptional regulation of the HIV-1 LTR by tatIII has also been observed in plasmid transfection experiments in COS cells (15) and is reported to operate through suppression of a termination of transcription that normally occurs -55 nucleotides 3' to the cap site, rather than by increasing the rate of initiation of transcription from the HIV-1 LTR (10).
The HIV-1 LTR contained in Ad is inactive in HeLa, H9, and Jurkat cells in the absence of either the tatIII or Ad 13S ElA proteins (Table 1; Fig. 3) . In HeLa cells, these transactivators can act separately or additively to stimulate HIV-1 LTR-directed transcription. While the action of tatIII is specific to the HIV-1 LTR, the 13S ElA protein also trans-activates the RSV LTR contained in Ad. A wide variety of both RNA polymerase II and III genes introduced into cells as plasmid DNAs or recombinant Ad is activated by the 13S protein, but in no case is the mechanism of action of the 13S protein clear. No DNA consensus sequence involved in 13S activity has been identified, and the 13S ElA protein is not thought to interact directly with DNA (39) . Rather, the 13S protein may stimulate the activity of cellular transcription factors, and the precise nature of the interaction between EMA and such factors may be promoter specific (40, 41) .
When the 13S protein, supplied by a coinfecting wild-type Ad, activates the HIV-1 LTR contained in the recombinant Ad, there is an::12-hr lag period prior to expression. This lag cannot be reduced by 14-hr preinfection with wild-type virus prior to infection with the recombinant Ad ( Table 5 ). The lag in expression is also observed in 293 cells, which constitutively express the 13S protein. These results support the model that the 13S protein acts to facilitate a cis modification of the HIV-1 LTR, such as assembly of a transcription complex, prior to transcription. Interestingly, the HIV-1 LTR contained in Ad, when trans-activated by tatIII, also undergoes a similar 12-hr lag prior to expression (Tables 1 and  3) .
Expression of the 13S EMA protein is required for Admediated trans-activation of the HIV-1 and RSV LTRs contained in Ad; the 12S and 9S proteins do not suffice. This activation does not involve expression of Ad late genes (Tables 1-3 ), but since expression of the 13S protein activates all the other early Ad promoters, additional early gene products may be involved. We have ruled out a role for the Ad EIB genes, as coinfection of HIV-1CAT-Ad with Ad mutants unable to express E1B proteins in both HeLa and HeLa/tatIII cells resulted in trans-activation equivalent to that seen with wild-type Ad (A.B.R. and E. White, unpublished results). We have also ruled out a role for the E3 gene, as coinfection of HIV-1CAT-Ad with Ad d1309, both deleted for E3, resulted in trans-activation (M. Laspia and A.P.R., unpublished results). We cannot at present rule out involvements of the E2 and E4 genes in coinfection experiments, although plasmid transfection experiments show they are not necessary for trans-activation (Table 4 ; ref. 19) . Because HIV-1CAT-Ad and RSVCAT-Ad encode the E2 and E4 genes, it will be necessary to construct additional recombinant Ad to resolve this issue.
Because the expression of CAT activity from HIV-1CAT-Ad is dependent on the presence of a trans-activator in the infected cell, recombinant Ad such as those described here have diagnostic potential.
Note Added in Proof. Nabel et al. (42) have also shown that the Ad 135 EMA protein trans-activates the HIV-1 LTR.
